LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

Search

Cerus Corp

Gesloten

SectorGezondheidszorg

1.65 0.61

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.63

Max

1.7

Belangrijke statistieken

By Trading Economics

Inkomsten

5.7M

-20K

Verkoop

253K

53M

Winstmarge

-0.038

Werknemers

614

EBITDA

4.8M

1.6M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+181.25% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

16M

307M

Vorige openingsprijs

1.04

Vorige sluitingsprijs

1.65

Nieuwssentiment

By Acuity

58%

42%

318 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Cerus Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 nov 2025, 21:55 UTC

Winsten

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

12 nov 2025, 21:34 UTC

Winsten

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

12 nov 2025, 23:44 UTC

Marktinformatie

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

12 nov 2025, 23:38 UTC

Marktinformatie

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

12 nov 2025, 23:13 UTC

Winsten

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

12 nov 2025, 23:13 UTC

Winsten

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

12 nov 2025, 23:13 UTC

Winsten

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

12 nov 2025, 23:13 UTC

Winsten

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

12 nov 2025, 22:30 UTC

Marktinformatie
Winsten

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

12 nov 2025, 22:18 UTC

Winsten

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

12 nov 2025, 22:12 UTC

Marktinformatie

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

12 nov 2025, 22:05 UTC

Winsten

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

12 nov 2025, 22:04 UTC

Winsten

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

12 nov 2025, 22:04 UTC

Winsten

Pan American Silver 3Q Adj EPS 48c >PAAS

12 nov 2025, 22:04 UTC

Winsten

Pan American Silver 3Q Rev $884.4M >PAAS

12 nov 2025, 22:04 UTC

Winsten

Pan American Silver 3Q EPS 45c >PAAS

12 nov 2025, 22:03 UTC

Winsten

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

12 nov 2025, 22:02 UTC

Winsten

Manulife Financial 3Q Net C$1.8B >MFC

12 nov 2025, 22:02 UTC

Winsten

Manulife Financial 3Q Adj EPS C$1.16 >MFC

12 nov 2025, 22:02 UTC

Winsten

Manulife Financial 3Q EPS C$1.02 >MFC

12 nov 2025, 21:53 UTC

Acquisities, Fusies, Overnames

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

12 nov 2025, 21:53 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

12 nov 2025, 21:53 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

12 nov 2025, 21:53 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

12 nov 2025, 21:52 UTC

Acquisities, Fusies, Overnames

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

12 nov 2025, 21:51 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

12 nov 2025, 21:50 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

12 nov 2025, 21:49 UTC

Winsten

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

12 nov 2025, 21:48 UTC

Winsten

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

12 nov 2025, 21:40 UTC

Winsten

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

Peer Vergelijking

Prijswijziging

Cerus Corp Prognose

Koersdoel

By TipRanks

181.25% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.5 USD  181.25%

Hoogste 5 USD

Laagste 4 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cerus Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Technische score

By Trading Central

1.3 / 1.36Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

318 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
help-icon Live chat